The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: From concept to clinical evaluation

Clinical Pharmacokinetics

Volumn 40, Issue 2, 2001, Pages 105-123

  Emerich, D F ^a   Dean, R L ^a   Osborn, C ^b   Bartus, R T ^a,c  

^a ALKERMES INC   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Alkermes Europe Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR AGONIST; CALCIUM; CARBOPLATIN; LOBRADIMIL; PHOSPHATIDYLINOSITOL;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CALCIUM CELL LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG UPTAKE; ENDOTHELIUM CELL; GLIOMA; HUMAN; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; TIGHT JUNCTION;

EID: 0035074592     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140020-00003     Document Type: Review

References (73)

1. Transport of small molecules through the blood-brain barrier: Biology and methodology
2. The blood-brain barrier as a target for pharmacological modulation
3. An overview of the multiple functions of the blood-brain barrier
4. Neuroactive peptides and amino acid at the blood-brain barrier: Possible implications for drug abuse
5. Biochemical opening of the blood-brain barrier
6. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier
7. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors
8. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors
9. Bioregulation of kinins: Kallikreins, kininogens and kinases
10. Some old and some new ideas on kinin metabolism
11. Role of bradykinin in the vascular permeability response induced by carrageenin in rats
12. Development of RMP-7: A novel bradykinin agoinst that increases delivery of chemotherapeutics to gliomas
13. RMP-7: Potential as an adjuvant to the drug treatment of brain tumours
14. Kinin receptor subtypes
15. Cloning and pharmacological characterization of a human bradykinin (B2) receptor
16. Expression cloning of a human B1 bradykinin receptor
17. Bradykinin receptors of cerebral microvessels stimulate phosphoinositide turnover
18. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells
19. Effects of bradykinin on permeability and diameter of pial vessels in vivo
20. Effects of bradykinin on pial arteries and arterioles in vitro and in situ
21. Role of peptidases in bradykinin-induced increase in vascular permeability in vivo
22. Pharmacology of bradykinin and related kinins
23. Induction of B1 receptors for kinins in the rabbit by a bacterial lipopolysaccharide
24. Bradykinin and inflammatory pain
25. The degradation of bradykinin (BK) and of des-Arg9-BK in plasma
26. New selective agonists for neurokinin receptors: Pharmacological tools for receptor characterization
27. Structure-activity studies of bradykinin and related peptides: B2-receptor antagonists
28. Permeability of the BBB by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system
29. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin
30. In vitro plasma metabolism of RMP-7
31. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7
32. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors
33. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7)
34. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist RMP-7
35. Intraarterial administration of the bradykinin agonist, RMP-7 and carboplatin: A toxicologic evaluation in swine
36. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7
37. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy
38. Evidence that Cereport's ability to increase permeability of rat gliomas in dependent upon extent of tumor growth: Implications for treating newly emerging tumor colonies
39. Angiogenesis
40. The effect of cellular microenvironment on vessels in the brain. Part 1: Vessel structure in tumour, peritumour and brain from humans with malignant glioma
41. Enhanced uptake of carboplatin into brain tumors with intravenous Cereport (RMP-7): Dramatic differences as a function of dosing parameters
42. Genes expressed in human tumor endothelium
43. Use of Cereport (RMP-7) to increase delivery of carboplatin to gliomas: Insight and parameters for intracarotid infusion via a single-lumen cannula
44. Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analogue, Cereport (RMP-7)
45. Assumptions from the radiotherapy of glioblastoma
46. The chemotherapy of high grade astrocytomas
47. Patterns of failure following treatment of glioblastoma and anaplatic astrocytoma
48. Central nervous system tumors
49. Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors
50. Enhanced cytokines delivery and intercellular adhesion molecule 1 (ICAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7
51. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
52. Intravenous Cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels and enhances survival
53. Intravenous Cereport (RMP-7) enhances delivery of carboplatin and increases survival in rats with metastatic tumors in the brain
54. Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain
55. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7
56. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas
57. Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas
58. A simplified technique for measurement of blood-brain barrier permeability using CT: Preliminary results of the effect of RMP-7
59. A Phase I study of intravenous Cereport (RMP-7) with carboplatin patients with progression of malignant glioma
60. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma
61. Clinical studies with the novel bradykinin analog RMP-7 and carboplatin in patients with glioma
62. Pharmacokinetics of carboplatin and RMP-7 in patients with recurrent malignant glioma
63. Intravenous carboplatin for recurrent malignant glioma: A phase II study
64. Survival following treatment with RMP-7 and carboplatin in malignant glioma who grade III-IV: Comparison with matched controls
65. Teniposide for brain metastases of small-cell lung cancer: A phase II study
66. Teniposide sometimes effective in brain metastases from non-small cell lung cancer
67. Bradykinin modulation of tumor vasculature I: Activation of B2 receptors increases delivery of chemotherpaeutic agents into solid peripheral tumors, enhancing their efficacy
68. Bradykinin modulation of tumor vasculature II: Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modify vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors